| 臺大學術典藏 |
2022-06-27T07:06:29Z |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
|
Bean J.; Brennan C.; Shih J.-Y.; Riely G.; Viale A.; Wang L.; Chitale D.; Motoi N.; Szoke J.; Broderick S.; Balak M.; Chang W.-C.; CHONG-JEN YU; Gazdar A.; Pass H.; Rusch V.; Gerald W.; Huang S.-F.; Yang P.-C.; Miller V.; Ladanyi M.; Yang C.-H.; Pao W. |
| 臺大學術典藏 |
2022-06-27T07:06:20Z |
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
|
Yang C.-H.; CHONG-JEN YU; Shih J.-Y.; Chang Y.-C.; Hu F.-C.; Tsai M.-C.; Chen K.-Y.; Lin Z.-Z.; Huang C.-J.; Shun C.-T.; Huang C.-L.; Bean J.; Cheng A.-L.; Pao W.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-10T06:11:15Z |
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
|
Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chang Y.-C.; Hu F.-C.; Tsai M.-C.; Chen K.-Y.; ZHONG-ZHE LIN; Huang C.-J.; Shun C.-T.; Huang C.-L.; Bean J.; Cheng A.-L.; Pao W.; Yang P.-C. |
| 臺大學術典藏 |
2021-09-01T01:54:28Z |
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
|
Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chang Y.-C.; Hu F.-C.; Tsai M.-C.; Chen K.-Y.; Lin Z.-Z.; Huang C.-J.; Shun C.-T.; Huang C.-L.; Bean J.; ANN-LII CHENG; Pao W.; Yang P.-C. |
| 臺大學術典藏 |
2021-08-11T03:46:53Z |
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
|
Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chang Y.-C.; Hu F.-C.; Tsai M.-C.; Chen K.-Y.; ZHONG-ZHE LIN; Huang C.-J.; Shun C.-T.; Huang C.-L.; Bean J.; Cheng A.-L.; Pao W.; Yang P.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:17Z |
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
|
Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chang Y.-C.; Hu F.-C.; Tsai M.-C.; KUAN-YU CHEN; Lin Z.-Z.; Huang C.-J.; Shun C.-T.; Huang C.-L.; Bean J.; Cheng A.-L.; Pao W.; Yang P.-C. |
| 臺大學術典藏 |
2021-03-19T06:57:52Z |
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
|
Yang C.-H.; Yu C.-J.; Shih J.-Y.; YEUN-CHUNG CHANG; Hu F.-C.; Tsai M.-C.; Chen K.-Y.; Lin Z.-Z.; Huang C.-J.; Shun C.-T.; Huang C.-L.; Bean J.; Cheng A.-L.; Pao W.; Yang P.-C. |
| 臺大學術典藏 |
2021-03-18T02:03:01Z |
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
|
Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chang Y.-C.; Hu F.-C.; Tsai M.-C.; Chen K.-Y.; Lin Z.-Z.; Huang C.-J.; CHIA-TUNG SHUN; Huang C.-L.; Bean J.; Cheng A.-L.; Pao W.; Yang P.-C. |
| 臺大學術典藏 |
2020-12-02T02:34:40Z |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
|
Bean J.; Brennan C.; Shih J.-Y.; Riely G.; Viale A.; Wang L.; Chitale D.; Motoi N.; Szoke J.; Broderick S.; Balak M.; Chang W.-C.; Yu C.-J.; Gazdar A.; Pass H.; Rusch V.; Gerald W.; Huang S.-F.; Pan-Chyr Yang; Miller V.; Ladanyi M.; Yang C.-H.; Pao W.; Bean J.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-08-13T06:34:03Z |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
|
Bean J.; Brennan C.; JIN-YUAN SHIH; Riely G.; Viale A.; Wang L.; Chitale D.; Motoi N.; Szoke J.; Broderick S.; Balak M.; Chang W.-C.; Yu C.-J.; Gazdar A.; Pass H.; Rusch V.; Gerald W.; Huang S.-F.; Yang P.-C.; Miller V.; Ladanyi M.; Yang C.-H.; Pao W.; Bean J.;Brennan C.;Jin-Yuan Shih;Riely G.;Viale A.;Wang L.;Chitale D.;Motoi N.;Szoke J.;Broderick S.;Balak M.;Chang W.-C.;Yu C.-J.;Gazdar A.;Pass H.;Rusch V.;Gerald W.;Huang S.-F.;Yang P.-C.;Miller V.;Ladanyi M.;Yang C.-H.;Pao W. |
| 臺大學術典藏 |
2020-08-13T06:34:01Z |
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
|
Yang P.-C.; Pao W.; Cheng A.-L.; Yang C.-H.; Yu C.-J.; JIN-YUAN SHIH; Chang Y.-C.; Hu F.-C.; Tsai M.-C.; Chen K.-Y.; Lin Z.-Z.; Huang C.-J.; Shun C.-T.; Huang C.-L.; Bean J. |
| 臺大學術典藏 |
2020-05-26T09:27:24Z |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
|
Bean J;Brennan C;Shih J.-Y;Riely G;Viale A;Wang L;Chitale D;Motoi N;Szoke J;Broderick S;Balak M;Chang W.-C;Yu C.-J;Gazdar A;Pass H;Rusch V;Gerald W;Huang S.-F;Yang P.-C;Miller V;Ladanyi M;Chih-Hsin Yang;Pao W.; Bean J; Brennan C; Shih J.-Y; Riely G; Viale A; Wang L; Chitale D; Motoi N; Szoke J; Broderick S; Balak M; Chang W.-C; Yu C.-J; Gazdar A; Pass H; Rusch V; Gerald W; Huang S.-F; Yang P.-C; Miller V; Ladanyi M; CHIH-HSIN YANG; Pao W. |
| 臺大學術典藏 |
2020-05-26T09:27:22Z |
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
|
Yang P.-C.;Pao W;Cheng A.-L;Bean J;Huang C.-L;Shun C.-T;Huang C.-J;Lin Z.-Z;Chen K.-Y;Tsai M.-C;Hu F.-C;Chang Y.-C;Shih J.-Y;Yu C.-J;Chih-Hsin Yang; CHIH-HSIN YANG; Yu C.-J; Shih J.-Y; Chang Y.-C; Hu F.-C; Tsai M.-C; Chen K.-Y; Lin Z.-Z; Huang C.-J; Shun C.-T; Huang C.-L; Bean J; Cheng A.-L; Pao W; Yang P.-C. |
| 臺大學術典藏 |
2018-09-10T06:32:51Z |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
|
PAN-CHYR YANG; JIN-YUAN SHIHet al.; CHONG-JEN YU; Bean, J.; Brennan, C.; Shih, J.-Y.; Riely, G.; Viale, A.; Wang, L.; Chitale, D.; Motoi, N.; Szoke, J.; Broderick, S.; Balak, M.; Chang, W.-C.; Yu, C.-J.; Gazdar, A.; Pass, H.; Rusch, V.; Gerald, W.; Huang, S.-F.; Yang, P.-C.; Miller, V.; Ladanyi, M.; Yang, C.-H.; Pao, W. |
| 國立臺灣大學 |
2008-06 |
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
|
Yang, CH; Yu, CJ; Shih, JY; Chang, YC; Hu, FC; Tsai, MC; Chen, KY; Lin, ZZ; Huang, CJ; Shun, CT; Huang, CL; Bean, J; Cheng, AL; Pao, W; Yang, PC. |
| 國家衛生研究院 |
2007-12-26 |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
|
Bean, J; Brennan, C; Shih, JY; Riely, G; Viale, A; Wang, L; Chitale, D; Motoi, N; Szoke, J; Broderick, S; Balak, M; Chang, WC; Yu, CJ; Gazdar, A; Pass, H; Rusch, V; Gerald, W; Huang, SF; Yang, PC; Miller, V; Ladany, M; Yang, CH; Pao, W |
| 國家衛生研究院 |
2007-12 |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
|
Bean, J;Brennan, C;Shih, JY;Riely, G;Viale, A;Wang, L;Chitale, D;Motoi, N;Szoke, J;Broderick, S;Balak, M;Chang, WC;Yu, CJ;Gazdar, A;Pass, H;Rusch, V;Gerald, W;Huang, SF;Yang, PC;Miller, V;Ladanyi, M;Yang, CH;Pao, W |
| 國家衛生研究院 |
2005-10 |
Linking C-reactive protein to latelife disability in the National Health and Nutrition Examination Survey (NHANES) 1999-2002
|
Kuo, H;Bean, J;Yen, C;Leveille, S |
